Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
NeuroPace ( (NPCE) ) has provided an update.
On February 20, 2025, NeuroPace announced the completion of its repurchase of 5,270,845 shares of its common stock from KCK Ltd., using proceeds from a recent public offering. This strategic move, along with the termination of its ATM equity offering program, has strengthened the company’s financial position, enabling it to focus on executing its long-term plans and reaching cash flow breakeven, while also demonstrating investor confidence in its mission.
More about NeuroPace
NeuroPace, Inc., based in Mountain View, California, is a medical device company dedicated to improving the lives of individuals with epilepsy through its RNS System. This system is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source, particularly benefiting those with drug-resistant epilepsy and potentially other brain disorders.
YTD Price Performance: 16.15%
Average Trading Volume: 155,010
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $401.2M
For a thorough assessment of NPCE stock, go to TipRanks’ Stock Analysis page.
